시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 알칼로이드 약물 시장 보고서(2025년)
Alkaloid Based Drugs Global Market Report 2025
상품코드 : 1750901
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,156,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,898,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,640,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

알칼로이드 약물 시장 규모는 향후 수 년간 강력한 성장이 전망될 예정입니다. 만성 질환의 유병률의 상승, 식물 유래의 의약품에 대한 수요 증가, 암 치료에의 폭넓은 응용, 대체 의료에 대한 인식 증가, 천연 의약품의 개발에 대한 정부의 지원 강화 등이 배경에 있습니다. 이 기간에 예상되는 주요 동향에는 알칼로이드 추출과 생합성에 있어서의 기술 진보, 알칼로이드 의약품 개발에의 인공지능의 통합, 알칼로이드 의약품 업계에 있어서의 전략적 합병과 인수, 약용 식물의 지속 가능한 재배 방법의 채택, 그리고 다중 표적 알칼로이드 기반 치료 솔루션의 발전이 있습니다.

감염증 증가는 알칼로이드 의약품 시장의 성장을 가속할 것으로 예상되고 있습니다. 이러한 질병의 전 세계적인 증가는 주로 국제 여행이 증가함에 따라 병원균이 지역과 대륙으로 빠르게 확산되어 더 빈번하고 광범위한 발병으로 이어지기 때문입니다. 2024년 12월, 스위스에 본부를 두는 전문기관인 세계보건기구(WHO)의 보고서에 따르면 2023년에는 전 세계에서 2억 6,300만명의 말라리아 환자가 발생했고 59만 7,000명이 사망했습니다. 이것은 2022년부터 약 1,100만건 증가한 것이지만, 사망자 수는 크게 변하지 않았습니다.

알칼로이드 약물 시장의 주요 기업은 장기적인 목표에 따라 혁신을 촉진하고 지속 가능한 경쟁력을 얻기 위해 전략적 투자를 추구하는 경향이 강해지고 있습니다. 이러한 투자에는 핵심 비즈니스 목표를 지원하고, 시장 포지셔닝을 개선하거나, 새로운 지리적 또는 치료 분야에 진출하기 위한 장기적인 재정적 약속이 포함됩니다. 2024년 10월, 마케도니아에 본사를 둔 알칼로이드 기반 의약품 제조업체인 Alkaloid AD Skopje는 바이오시밀러 의약품의 시장 도입을 촉진하기 위해 한국에 본사를 둔 연구 개발 회사인 Rophibio에 100만 달러를 투자했습니다. 이 파트너십을 통해 알칼로이드 AD는 Rophibio의 혁신적인 의약품 개발에 대한 접근에 액세스할 수 있으며, 성장을 가속화하고 신흥국 시장에서의 입지를 확대함으로써 알칼로이드 AD의 전략적 야심을 지원합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Alkaloid-based drugs are pharmaceuticals derived from naturally occurring alkaloids found in plants, fungi, and animals. These substances often exert strong effects on the human body, especially the nervous system, and are utilized for treating a variety of medical conditions due to their therapeutic benefits.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary categories of alkaloid-based drugs include true alkaloids, protoalkaloids, and pseudoalkaloids. True alkaloids are nitrogen-containing organic compounds that originate from amino acids, are predominantly found in plants, and possess significant pharmacological effects-examples include morphine and quinine. These drugs can be administered orally, intravenously, or through other methods, and are used for purposes such as analgesic, antimalarial, antibacterial, anticancer, cholinomimetic, antiasthma, antiarrhythmic, vasodilatory, and antihyperglycemic treatments. They are utilized by a range of end users, including clinics, hospitals, and other healthcare facilities.

The alkaloid based drugs market research report is one of a series of new reports from The Business Research Company that provides alkaloid based drugs market statistics, including alkaloid based drugs industry global market size, regional shares, competitors with a alkaloid based drugs market share, detailed alkaloid based drugs market segments, market trends and opportunities, and any further data you may need to thrive in the alkaloid based drugs industry. This alkaloid based drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alkaloid-based drugs market size has grown strongly in recent years. It will grow from$2.89 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth during the historical period can be attributed to the rising prevalence of pain-related conditions, increased investment in pharmaceutical research and development, expansion of the opioid and analgesic markets, growing demand for plant-based medications, a higher incidence of cancer, and an increase in mental health disorders.

The alkaloid-based drugs market size is expected to see strong growth in the next few years. It will grow to$4.52 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The projected growth in the forecast period can be attributed to the rising prevalence of chronic illnesses, increasing demand for plant-based pharmaceuticals, broader applications in cancer therapies, growing awareness of alternative medicine, and enhanced government support for the development of natural drugs. Key trends expected during this period include technological progress in alkaloid extraction and biosynthesis, the integration of artificial intelligence into alkaloid drug development, strategic mergers and acquisitions within the alkaloid pharmaceutical industry, the adoption of sustainable cultivation practices for medicinal plants, and the advancement of multi-target alkaloid-based therapeutic solutions.

The rising prevalence of infectious diseases is expected to drive the growth of the alkaloid-based drugs market. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, can spread from person to person either directly or indirectly. The global increase in these diseases is largely due to growing international travel, which allows pathogens to spread quickly across regions and continents, leading to more frequent and widespread outbreaks. Alkaloid-based drugs are essential in managing infectious diseases because they contain powerful bioactive compounds capable of effectively inhibiting or destroying pathogens, thus aiding in infection control and eradication. For example, in December 2024, a report by the World Health Organization (WHO), a specialized agency based in Switzerland, estimated that there were 263 million malaria cases and 597,000 related deaths globally in 2023. This marked an increase of approximately 11 million cases from 2022, although the number of deaths remained largely unchanged. Consequently, the growing incidence of infectious diseases is expected to boost the alkaloid-based drugs market.

Key players in the alkaloid-based drugs market are increasingly pursuing strategic investments to align with their long-term goals, foster innovation, and gain a sustainable competitive edge. These investments involve long-term financial commitments aimed at supporting core business objectives, improving market positioning, or entering new geographic or therapeutic areas. For instance, in October 2024, Alkaloid AD Skopje, a Macedonia-based manufacturer of alkaloid-based drugs, invested $1 million in Rophibio, a research and development firm based in South Korea, to facilitate the introduction of biosimilar drugs into the market. This investment grants Alkaloid AD ownership interests and first refusal rights for licensing products in the region, enhancing its role in the biopharmaceutical sector. Through this partnership, Alkaloid AD gains access to Rophibio's innovative drug development efforts, supporting its strategic ambitions by accelerating growth and expanding its presence in emerging markets.

In January 2023, Sterling Pharma Solutions, a contract development and manufacturing organization (CDMO) based in the United States, acquired Novartis' active pharmaceutical ingredient (API) manufacturing facility located in Ringaskiddy, Ireland, for an undisclosed amount. This acquisition increases Sterling's capacity to meet the growing demand for API manufacturing services. The transaction also includes a supply agreement under which Sterling will continue producing several APIs for Novartis, specifically for use in cardiovascular, immunology, and oncology treatments at the Ringaskiddy facility. Novartis AG, based in Switzerland, is a key manufacturer of alkaloid-based drugs.

Major players in the alkaloid based drugs market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Eli Lilly and Company, Merck Group, Boehringer Ingelheim, Mylan NV, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Zydus Cadila, Lupin Limited, Alchem International Pvt. Ltd., Verve Health Care LTD., AdvaCare Pharma, Vital Laboratories Pvt Ltd.

North America was the largest region in the alkaloid-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in alkaloid-based drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alkaloid-based drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alkaloid-based drugs market consists of sales of respiratory stimulants, muscle relaxants, and cardiovascular drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alkaloid Based Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alkaloid based drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for alkaloid based drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alkaloid based drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

3) By Pseudoalkaloids; Terpenoid Alkaloids; Steroidal Alkaloids; Peptide Alkaloids

Table of Contents

1. Executive Summary

2. Alkaloid Based Drugs Market Characteristics

3. Alkaloid Based Drugs Market Trends And Strategies

4. Alkaloid Based Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Alkaloid Based Drugs Growth Analysis And Strategic Analysis Framework

6. Alkaloid Based Drugs Market Segmentation

7. Alkaloid Based Drugs Market Regional And Country Analysis

8. Asia-Pacific Alkaloid Based Drugs Market

9. China Alkaloid Based Drugs Market

10. India Alkaloid Based Drugs Market

11. Japan Alkaloid Based Drugs Market

12. Australia Alkaloid Based Drugs Market

13. Indonesia Alkaloid Based Drugs Market

14. South Korea Alkaloid Based Drugs Market

15. Western Europe Alkaloid Based Drugs Market

16. UK Alkaloid Based Drugs Market

17. Germany Alkaloid Based Drugs Market

18. France Alkaloid Based Drugs Market

19. Italy Alkaloid Based Drugs Market

20. Spain Alkaloid Based Drugs Market

21. Eastern Europe Alkaloid Based Drugs Market

22. Russia Alkaloid Based Drugs Market

23. North America Alkaloid Based Drugs Market

24. USA Alkaloid Based Drugs Market

25. Canada Alkaloid Based Drugs Market

26. South America Alkaloid Based Drugs Market

27. Brazil Alkaloid Based Drugs Market

28. Middle East Alkaloid Based Drugs Market

29. Africa Alkaloid Based Drugs Market

30. Alkaloid Based Drugs Market Competitive Landscape And Company Profiles

31. Alkaloid Based Drugs Market Other Major And Innovative Companies

32. Global Alkaloid Based Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Alkaloid Based Drugs Market

34. Recent Developments In The Alkaloid Based Drugs Market

35. Alkaloid Based Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기